TERMINATEDPhase 4

BOTOX Effects on Seizure Severity and Susceptibility

NCT05605756•Beth Israel Deaconess Medical Center

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Drug-resistant Focal Seizure

Interventions

OnabotulinumtoxinA 145 UNT [Botox]

Locations

1

United States

Locations (1)

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Key Dates

Start Date

March 1, 2023

Primary Completion Date

December 1, 2024

Completion Date

December 1, 2024

Last Updated

January 23, 2025

Sponsors

Lead Sponsor

Beth Israel Deaconess Medical Center

Collaborators

AbbVie

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 23, 2025Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions